Transgenic mice expressing Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) under the control of an immunoglobulin heavy-chain promoter and enhancer develop lymphoma at a threefold higher incidence than LMP1-negative mice. In vitro, LMP1 activates numerous signaling pathways including p38, c-Jun N terminal kinase (JNK), phosphatidylinositol 3 kinase (PI3K)/Akt, and NF-jB through interactions with tumor necrosis receptorassociated factors (TRAFs). These pathways are frequently activated in EBV-associated malignancies, although their activation cannot be definitively linked to LMP1 expression in vivo. In this study, interactions between LMP1 and TRAFs and the activation of PI3K/ Akt, JNK, p38, and NF-jB were examined in LMP1 transgenic mice. LMP1 co-immunoprecipitated with TRAFs 1, 2, and 3. Akt, JNK, and p38 were activated in LMP1-positive and -negative splenocytes as well as LMP1-positive and -negative lymphomas. Multiple forms of NF-jB were activated in healthy splenocytes from LMP1 transgenic mice, in contrast to healthy splenocytes from LMP1-negative mice. However, in both LMP1-positive and -negative lymphomas, only the oncogenic NF-jB c-Rel, was specifically activated. Similarly to EBV-associated malignancies, p53 protein was detected at high levels in the transgenic lymphomas, although mutations were not detected in the p53 gene. These data indicate that NF-jB is activated in LMP1-positive healthy splenocytes; however, NF-jB c-Rel is specifically activated in both the transgenic lymphomas and in the rare lymphomas that develop in negative mice. The LMP1-mediated activation of NF-jB may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.
Introduction
Epstein-Barr virus (EBV) is a gammaherpesvirus associated with epithelial and lymphoid human malignancies such as nasopharyngeal carcinoma (NPC), Burkitt's lymphoma, Hodgkin's lymphoma, nasal T-/NK cell lymphoma, post-transplant lymphoproliferative diseases, and AIDS-associated lymphoma. Latent membrane protein 1 (LMP1) is considered the EBV oncogene as it can transform rodent fibroblast (Arrand et al., 1981; Wang et al., 1985; Moorthy and Thorley-Lawson, 1993) , supports anchorage-independent growth in soft agar (Baichwal and Sugden, 1988) , and when expressed in Rat-1 cells is tumorigenic in nude mice (Wang et al., 1985) . With the exception of Burkitt's lymphoma, LMP1 is expressed in all EBV-associated human lymphoid malignancies.
LMP1 has two main signaling regions, the membrane proximal signaling region, C-terminal-activating region 1 (CTAR1 or TES1), and the membrane terminal region, C-terminal-activating region 2 (CTAR2 or TES2). While LMP1 has little primary sequence homology to any other protein, it is functionally analogous to a tumor necrosis factor receptor (TNFR) or CD40 (Mosialos et al., 1995) . LMP1 and CD40 both have PXQXT motifs, which bind cellular adapter proteins, TNFR-associated factors (TRAFs) Franken et al., 1996) . LMP1 can partially substitute for CD40 function in vivo and induces extrafollicular B-lymphocyte differentiation in LMP1-positive CD40 null mice (Uchida et al., 1999) . Transgenic CD40 null mice expressing only chimeric CD40/ LMP1 molecules with the LMP1 intracellular carboxyterminus also displayed normal isotype switching and affinity maturation with marked splenomegaly (Stuntz et al., 2004) . CTAR1 binds TRAFs 1, 2, 3, and 5 Miller et al., 1998) and CTAR2 binds TNFR-associated death domain protein and receptor-interacting protein (Izumi and Kieff, 1997; Izumi et al., 1999) .
Unlike TNFR or CD40, LMP1 aggregates through its transmembrane domains and constitutively associates with TRAFs in a ligand-independent manner Franken et al., 1996) . The constitutive activation of this signaling pathway was proven in vivo in transgenic mice expressing chimeric LMP1/CD40 with the transmembrane domains of LMP1 fused to the carboxy signaling domains of CD40 (Panagopoulos et al., 2004) . These mice had dramatic upregulation of CD69, CD80, and CD86, which are known targets of CD40 signaling, and greatly increased serum IgM. Association of LMP1 with TRAFs results in the activation of the NF-kB family of transcription factors from both CTAR1 and CTAR2 (Hammarskjold and Simurda, 1992; Paine et al., 1995; Miller et al., 1998) . In addition to the activation of the NF-kB pathway, LMP1 activates numerous other signaling pathways including cdc42, p38 pathway, c-Jun N-terminal kinase (JNK) pathway, and the phosphatidylinositol 3 kinase (PI3K)/ Akt pathway (Eliopoulos and Young, 2001; Dawson et al., 2003) . The activation of several of these pathways likely confers a growth advantage. LMP1 has also been shown to affect apoptosis and through upregulation of A20 specifically blocking p53-mediated apoptosis (Fries et al., 1996) . While the p53 gene is frequently mutated in human malignancies, it is rarely mutated in EBV-associated malignancies, suggesting that the effects of EBV on p53 function eliminate a selection for mutation in p53 (Effert et al., 1992; Edwards and Raab-Traub, 1994) .
To further characterize the LMP1 signaling pathways in vivo, three lineages of LMP1 transgenic mice under the control of an immunoglobulin heavy-chain promoter and enhancer were developed. The LMP1 transgenic mice had a threefold increase in lymphoma development in comparison with LMP1-negative mice (Kulwichit et al., 1998) . As LMP1 is the only EBV gene expressed in the transgenic lymphomas, the LMP1 mouse lymphoma model offers an excellent opportunity to examine LMP1 signaling pathways in vivo. In this study, the LMP1 transgenic lymphomas were analysed to examine activation of the signaling pathways known to be affected by LMP1 expression. In lymphoma samples, LMP1 associated with TRAFs 1, 2, and 3. Phosphorylation of Akt, p38, and JNK were detected in both LMP1-positive and -negative lymphomas as well as healthy splenocytes. Activated NF-kB was also detected in both healthy LMP1-positive and -negative splenocytes; however, multiple heterodimeric forms of NF-kB were detected by electromobility shift assay (EMSA) in LMP1-positive splenocytes. In contrast, in LMP1-positive and -negative lymphomas, only activation of c-Rel was specifically detected. Finally, it was determined that, similar to EBV-associated human malignancies, p53 was rarely mutated in LMP1-positive lymphomas. These data confirm that LMP1 signaling is functional in the transgenic lymphomas and suggest that activation of a specific form of NF-kB is a critical event in the development of lymphoma.
Results
LMP1 co-immunoprecipitates with TRAFs 1, 2, and 3 in vivo Interactions between TRAFs and LMP1 have been implicated in LMP1 activation of signaling pathways and have been detected in EBV-induced post-transplant lymphomas (Mosialos et al., 1995; Liebowitz, 1998) . To determine if LMP1 was similarly functional in vivo, interactions with TRAFs were examined in LMP1 transgenic lymphomas. Lysates from LMP1 transgenic lymphomas or LMP1-negative spontaneous lymphoma tissues were precleared with mouse IgG1, immunoprecipitated with a-LMP1 CS1-4 mouse IgG1 monoclonal antibody or isotype control, and immunoblotted for LMP1 and TRAFs 1, 2, and 3 (Figure 1 ). LMP1 was detected in Raji cell lysate-positive control and the LMP1 transgenic lymphoma lysates (L1, L2, and L3) immunoprecipitated with CS1-4 ( Figure 1a , and LMP1-negative spontaneous lymphoma (C) were made with NP40 lysis buffer. Lysates were immunoprecipitated with the a-LMP1 CS1-4 and used for a TRAF1 Western blot. Raji cell lysates were used as a positive control. (b) NP40 lysates from LMP1-positive lymphomas (L2 and L3) and LMP1-negative spontaneous lymphoma (C) were immunoprecipitated with IgG1-negative isotype control (G1) or a-LMP1 CS1-4. IPs were blotted for LMP1 and TRAF2. Cord blood cells infected with the B95-8 strain of EBV (CB) lysates directly loaded onto the SDS-PAGE gel were used as a positive control for the LMP1 and TRAF2 Western blots. (c) NP40 lysates from LMP1-positive lymphoma (L3) and LMP1-negative spontaneous lymphoma (C) were immunoprecipitated with IgG1 isotypenegative control (G1) or a-LMP1 CS1-4 and blotted for LMP1 and TRAF3.
To examine the interaction between LMP1 and TRAF2 in vivo, LMP1-positive and -negative lysates were immunoprecipitated with IgG1 isotype control (G1) or CS1-4 and used for a TRAF2 immunoblot (Figure 1b) . Cord blood cells infected with the B-958 strain of EBV were directly loaded onto the SDS-PAGE gel and used as a positive control for the LMP1 and TRAF2 immunoblots (Figure 1b, lane 1) . Immunoprecipitation with isotype control did not immunoprecipitate LMP1 or TRAF2 in the LMP1-positive lymphomas (L2 and L3) (Figure 1b, lanes 2 and 3) . However, LMP1 did immunoprecipitate with TRAF2 in LMP1-positive lymphomas but not the LMP1-negative lymphoma, confirming an in vivo interaction (Figure 1b , lanes 4-6). The interaction between LMP1 and TRAF3 was also examined by co-immunoprecipitation in an LMP1-positive and -negative lymphoma. Immunoprecipitation with IgG1 isotype control did not precipitate TRAF3 ( Figure 1c, lanes 1 and 3) . However, LMP1 and TRAF3 did co-immunoprecipitate in the LMP1-positive lymphoma (L3) ( Figure 1c , lane 2) but not the LMP1-negative lymphoma (C) (Figure 1c , lane 4). The co-immunoprecipitation of LMP1 with TRAFs was also detected in other LMP1 transgenic lymphomas using the a-LMP1 OT22C mouse monoclonal antibody and a-LMP1D rabbit polyclonal antibody (data not shown). These data confirm in vivo interactions between LMP1 and TRAFs 1, 2, and 3, indicating that downstream signaling events dependent on LMP1-TRAF interactions may be active.
Akt, p38, and JNK activated in LMP1-positive and -negative splenocytes and lymphomas LMP1 has been shown to activate the PI3K/Akt pathway through CTAR1, the p38 mitogen-activated protein kinase cascade through both CTAR1 and CTAR2, and the JNK signaling pathway through the CTAR2 region (Eliopoulos et al., 1999a, b; Dawson et al., 2003) . To identify the activation of signaling pathways in the transgenic lymphomas, phosphospecific, activated forms were detected by immunoblot of whole-cell lysates from cultured splenocytes. Splenocytes of healthy LMP1-positive and -negative mice were obtained from disaggregated spleens. Flourescenceactivated cell scanning (FACS) analysis for B220 and CD3 indicated that these preparations were approximately 65% B cells and 25% T cells (data not shown) with equivalent proportions in the LMP1 transgenic and BalbC control spleens. Lymphoma samples were passaged in SCID mice to enrich for malignant cells and were determined to be 99% B cells. Phosphospecific, activated Akt was detected in LMP1-negative and -positive normal splenocytes (C and L) as well as in SCIDpassaged LMP1-positive and -negative lymphomas (CL, LL1 and LL3) and in a snap-frozen primary LMP1 lymphoma (L2) with equivalent detection of total Akt in all samples (Figure 2a ). Phosphorylated, activated JNK1 was detected in LMP1-positive and -negative normal splenocytes and SCID-passaged LMP1-positive lymphomas but not in the one LMP1-negative lymphoma, while total levels of total JNK were equivalent ( Figure 2b ). Phosphorylated, activated p38 was detected in LMP1-negative (C) and LMP1-positive (L) normal splenocytes as well as SCID-passaged LMP1-negative (CL) and LMP1-positive (L) lymphomas (Figure 2c ). Equal loading was confirmed through total p38 and b-actin immunoblots (Figure 2c , bottom panels). These data indicate that the PI3K/Akt, p38, and JNK pathways were all activated in vivo in normal mouse splenocytes and lymphomas and that activation was not dependent on LMP1 expression.
NF-kB, p65, and RelB activated in LMP1-positive, normal splenocytes LMP1 activation of NF-kB is dependent on interactions with TRAFs 1, 2, and 3 Miller et al., 1997 Miller et al., , 1998 . To identify activation of NF-kB, nuclear extracts from splenocytes of BalbC nontransgenic mice and LMP1-positive transgenic mice were incubated with radiolabeled UV21 oligonucleotide probe with the NF-kB consensus site in the H-2K NF-kB c-Rel activated in LMP1-positive and -negative lymphomas LMP1 differentially activates NF-kB in different cellular contexts. In epithelial cells, LMP1 activates p50 homodimers, p50/p52, and p52/p65 heterodimers, as well as RelB (Paine et al., 1995; Miller et al., 1998; Eliopoulos et al., 2003a) . In B-lymphocytes, LMP1 also activates RelB (Pai et al., 2002) . In NPC, p50 homodimers bound to Bcl-3 are specifically activated (Thornburg et al., 2003) . To analyse NF-kB activation in the transgenic lymphoma samples, nuclear lysates from LMP1-positive and -negative lymphomas were analysed by EMSA (Figure 4) . Nuclear extracts from the splenocytes of healthy control had generally lower levels of activated NF-kB (Figure 4 , lanes 21-24), while most lymphomas had high levels of activated NF-kB ( Figure 4 , lanes 2-13 and 15-20) with equivalent levels in LMP1 DNApositive ( þ ) and DNA-negative (À) lymphomas. Furthermore, differences in NF-kB activation between lymphomas diagnosed as histiocytic lymphomas and lymphocytic lymphomas were not detected.
To identify the NF-kB family members activated in the lymphoma samples, supershift analysis was performed with three LMP1-positive and one LMP1-negative lymphoma samples using NF-kB-specific antibodies. In each sample, the complexes shifted with the a-c-Rel antibody (Figure 5a , lanes 6 and 12, and
Figure 5b, lanes 6 and 12). The complex in S7 also shifted with a-p65 and a-RelB antibodies (Figure 5b , lanes 5 and 7). Two additional LMP1-positive and one additional LMP1-negative samples were also used for supershift analysis, and all shifted only with the a-c-Rel antibody (data not shown). These data reveal that several forms of NF-kB are activated by LMP1 expression in healthy splenocytes, while, in lymphoma, c-Rel is specifically activated in the presence or absence of LMP1. These findings suggest that activation of c-Rel may be a critical step in the development of lymphoma.
Upregulation of TRAF1
TRAF1 expression is tissue restricted to lungs and lymphoid organs and is upregulated in B-lymphocytes by EBV infection (Mosialos et al., 1995) . In a study analysing TRAF1 expression in various human lymphoid populations, the protein was expressed at very low levels in normal lymphoid tissues and in almost all EBV-negative non-Hodgkin's lymphoma (HD), but at consistently high levels in EBV-associated HD (Durkop et al., 1999) . Like EBV-associated HD, TRAF1 was consistently overexpressed in LMP1-positive (L1-5) transgenic lymphomas, and was only expressed at high levels in one of three LMP1-negative lymphomas (C1-3) (Figure 6a ). Equal loading was confirmed by b-actin immunoblot (Figure 6a , bottom panel). This finding was consistent with results obtained by immunofluorescence staining on cryostat sections of these tissues, where TRAF1 stained more strongly in LMP1-associated lymphoma sections (data not shown). These data confirm that LMP1 is functional and that LMP1 target genes are upregulated. Edwards and Raab-Traub, 1994; Levine, 1997) . Mutations in p53 were examined by DNA sequencing analysis of LMP1-positive and -negative lymphomas, normal mouse spleens, with or without LMP1, as well as LMP1-containing splenic hyperplasia. Functionally significant amino-acid changes were only detected in one of eight LMP1-negative lymphoma samples (BL6.1, Table 1 ) but not in 37 LMP1 transgenic lymphoma samples. To examine potential allelic loss of p53 in the mouse lymphomas, p53 was also analysed by differential PCR. Differential PCR of the lymphomas in comparison to the b-globin gene indicated that the lymphomas did not have allelic loss of p53 within coding exons 5, 6, 7, or 8 (data not shown). These results mirror the status of p53 in human EBV-associated lymphomas and indicate that p53 is not mutated in the mouse lymphomas (Edwards and Raab-Traub, 1994) .
LMP1 has also been suggested to induce p53 expression in resting human B cells through NF-kB induction, resulting in the accumulation of p53 protein and elevated levels of p53 detected in NPC (Niedobitek et al., 1993; Chen and Cooper, 1996) . To detect effects of LMP1 expression on p53 protein levels, immunoblot analysis for p53 in whole-cell extracts from lymphomas in transgenic and control mice revealed consistently high levels of p53 in all LMP1 transgenic lymphomas (L1-5), while spontaneous LMP1-negative counterparts demonstrated lower and variable levels of p53 (C1-3) (Figure 6b ). Equal protein loading was confirmed by b-actin immunoblot (Figure 6b, bottom panel) . Taken together, these data indicate that in the LMP1 transgene model for lymphoma, the p53 coding sequence is not mutated, and the protein is expressed at increased levels, similar to EBV-positive cancers.
Discussion
LMP1 transgenic mice under the control of an immunoglobulin heavy-chain promoter and enhancer develop B-cell lymphoma over three times more frequently than age-matched negative controls (Kulwichit et al., 1998) . In this model, LMP1 is expressed in the lymphoma tissues at high levels and several oncogenes, including A20, Bcl-2, and c-Myc, are upregulated in LMP1-expressing lymphomas compared to LMP1-negative counterparts (Kulwichit et al., 1998) . These LMP1 transgenic mouse lymphomas offer an excellent opportunity to identify pathways activated by LMP1 in vivo that contribute to malignancy. 
Signaling and activation of NF-jB in LMP1 transgenic mice NJ Thornburg et al
Wild-type p53 negatively regulates cell growth, and mutations in the p53 gene are one of the most common genetic abnormalities found in human cancers (Nigro et al., 1989) . However, the p53 gene is rarely mutated in EBV-associated cancer (Ballerini et al., 1993; Edwards and Raab-Traub, 1994) . Like EBV-associated malignancies, the LMP1 transgenic mouse model lack mutations in the p53 gene (Table 1) , although the p53 protein is highly expressed in LMP1 transgenic lymphomas. This indicates that LMP1-induced lymphomas retain the ability to bypass the growth inhibitory characteristics of wild-type p53. Data in cell culture indicate that LMP1 upregulates A20, which can block p53-mediated apoptosis (Laherty et al., 1992; Fries et al., 1996) . Furthermore, LMP1 represses p53-mediated DNA repair and transcriptional activity and this activity is dependent on the NF-kB pathway (Liu et al., 2005) . The presence of elevated p53 protein and lack of mutations in LMP1-positive mouse lymphomas suggests that LMP1 also affects p53 expression and function in vivo.
Mimicking activated TNF receptors, LMP1 associates with TRAFs 1, 2, 3, and 5 in vitro. Furthermore, LMP1 colocalizes with TRAFs 1, 2, and 3 in HD and NPC (Ardila-Osorio et al., 1999; Murray et al., 2001) . Like the in vitro model as well as human malignancies, LMP1 colocalizes in vivo with TRAFs 1, 2, and 3 in transgenic LMP1 lymphomas (Figure 1) . Furthermore, TRAF1 is consistently upregulated in LMP1 transgenic lymphomas, in contrast to lower, variable levels of the protein in the spontaneous counterparts. This finding confirms previous studies, showing TRAF1 is upregulated in EBV-infected and LMP1-transfected cell lines (Mosialos et al., 1995; Devergne et al., 1998) . In addition, TRAF1 is upregulated in EBV-associated HD and some lymphoproliferative diseases and is necessary for LMP1-mediated JNK activation (Durkop et al., 1999; Eliopoulos et al., 2003b) . TRAF1 is an adapter protein that mediates NF-kB activation by members of the TNFR superfamily, including LMP1 . Upregulation of TRAF1 in LMP1 transgenic lymphomas may contribute to inhibition of apoptosis and to JNK activation and thereby promote development of lymphomas.
The TRAF proteins serve as intermediate for activation of various intracellular signaling pathways, including NF-kB and JNK activation (Dempsey et al., 2003) . LMP1 activates p38 through both CTAR1 and CTAR2 regions and consequently upregulate IL 6 and IL 8 (Eliopoulos et al., 1999b) . In the mouse lymphomas and normal splenocytes, Akt, p38, and JNK were activated and the activation was not dependent on LMP1 expression (Figure 2 ). These data indicate that activation of Akt, p38, or JNK is not specific for lymphoma development. In contrast, activation of NF-kB was elevated in LMP1-positive splenocytes, which had multiple forms of NF-kB in comparison to control splenocytes. The majority of lymphomas, independent of LMP1 expression, had elevated activated NF-kB as compared to normal splenocytes. These data suggest that activation of NF-kB may contribute to the development of the lymphoma and that in the absence of LMP1 expression, NF-kB may be activated via different mechanisms. Activated NF-kB is detected in EBV-positive HD, which is necessary for proliferation, and compensating mutations have been detected in EBV-negative HD that result in NF-kB activation (Bargou et al., 1997) . In HD and HD cell lines lacking LMP1, ikba is frequently mutated (Cabannes et al., 1999; Emmerich et al., 1999) . Similarly, NF-kB is activated in NPC either by the expression of LMP1 or through mutation or deletion of ikba (Thornburg et al., 2003) . The activation of the NF-kB pathway in both LMP1-positive and -negative lymphomas suggests that this activation is a contributing factor in the development of the tumor. Activation can occur either through the expression of LMP1 resulting in increased rates of lymphoma development or possibly through genetic changes that may occur in the rare spontaneous lymphoma.
An intriguing aspect of the transgenic lymphoma is that while all B cells express LMP1, the lymphomas that develop are clonal, indicating that a relatively rare cell has progressed to malignancy. The results presented in this study reveal that a distinct form of NF-kB is specifically activated in lymphoma compared with healthy splenocytes. Complexes containing NF-kB p65 and RelB were activated in healthy LMP1-positive splenocytes, whereas c-Rel was universally activated in both LMP1-positive and -negative lymphomas. These data suggest an essential role for c-Rel in the development of lymphoma. c-Rel is the only mammalian NF-kB family member that can transform lymphoid cells in vitro (Gilmore et al., 2001 ). While neither LMP1 or EBV have been implicated in activation of c-Rel, the PI3K/ Akt pathway may function to activate c-Rel (Andjelic et al., 2000) . The activation of PI3K/Akt pathway and the oncogenic NF-kB c-Rel likely upregulate numerous survival signals and the data presented here indicate that they also promote malignancy.
Materials and methods

Generation of LMP1 transgenic mice
Three LMP1 transgenic mouse lineages under the control of immunoglobulin heavy-chain enhancer and promoter were developed as previously described and have been maintained as heterozygotes on a BalbC background (Kulwichit et al., 1998) . Mice older than 12 months develop lymphoma with enlarged spleens with a three-to fourfold increased incidence in comparison with age-matched negative controls. Spleens were harvested from LMP1-negative and -positive littermates and sections of tissue were fixed and stained for histopathologic evaluations. The remaining tissues were either snapfrozen at À801C for analysis or used to prepare splenocytes for in vitro studies or passage in SCID mice.
Preparation of protein lysates
Frozen tissues were pulverized and resuspended in radioimmunoprecipitation assay buffer (RIPA) (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholic acid) supplemented with protease inhibitor cocktail (Sigma) for direct immunoblot analysis, or in nonidet P-40 (NP40) lysis buffer supplemented with protease inhibitor cocktail (Sigma) for co-immunoprecipitation assays (0.5% NP40, 50 mM HEPES, pH 7.3, 250 mM NaCl, 2 mM EDTA, 10% glycerol, 100 mg/ml PMSF, 3 mg/ml aprotinin, and 6 mg/ml leupeptin) at 41C (Figures 1 and 6) . Quantitation of protein lysates was performed using Bio-Rad D C Protein Assay.
Alternatively, spleen tissue obtained from BalbC and LMP1 transgenic mice was disaggregated and red blood cells were lysed in 0.8% ammonium chloride solution (Stemcell Technologies) for 10 min on ice, and washed twice in Iscove's medium containing 10% FBS and 1% antibiotic/antimycotic solution (Gibco). Cell lysates were prepared by washing the cell pellet twice in PBS and lysed in RIPA buffer supplemented with 2 mM PMSF, 1 mM Na 3 VO 4 and 1:100 protease/ phosphatase inhibitor cocktails (Sigma). Lymphomas were passaged by injecting 1 Â 10 8 splenocytes intraperitoneally into a SCID mouse. SCID mice that developed an extended abdomen were killed by CO 2 inhalation and the enlarged spleens were harvested. Samples were centrifuged at 7500 g for 10 min at 41C, and the supernatants were collected for further analysis (Figure 2) .
Preparation of nuclear and cytoplasmic extracts Nuclear and cytoplasmic extracts were prepared from frozen tissues as described previously (Thornburg et al., 2003) . Frozen tissues were pulverized using a B Braun Mikro-Dismembrator II. Pulverized tissue was washed once with cold PBS. Tissue cells were lysed by incubation in a hypotonic buffer (20 mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, protease and phosphatase inhibitor cocktails (Sigma)) for 15 min on ice followed by the addition of NP40 to a final concentration of 1%. The nuclear pellet was further purified using Optiprep (Sigma) reagent as directed by the manufacturer. The nuclear pellet was lysed with nuclear extraction buffer (20 mM Tris, pH 8.0, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, protease inhibitor cocktail (Sigma), and phosphatase inhibitor cocktail (Sigma)) with the salt concentration adjusted to 400 mM with 5 M NaCl.
Co-immunoprecipitation of LMP1 and TRAFs 1, 2, and 3 NP40 lysates were precleared by incubating with mouse IgG1 (Dako) at 1 mg/500 mg lysates and 20 ml of Gamma bind plus sepharose beads (Amersham)/500 mg of lysates at 41C on a nutator for 30 min. Samples were centrifuged at 1000 g for 5 min, and the supernatants were collected. CS1-4, a mouse monoclonal anti-LMP1 (Dako), or a corresponding isotypenegative control (mouse IgG1) (Dako) was added to the precleared lysates and nutated at 41C for 1 h. Gamma bind plus sepharose beads were then added at 20 ml/500 ml of lysates and the samples were nutated at 41C for 1 h. The beads were washed twice with NP40 buffer and once with cold PBS, resuspended in 1 Â SDS sample buffer, and boiled for 5 min. SDS-PAGE was performed using 8.5% gel.
Immunoblot analysis
Protein samples were separated by SDS-PAGE and transferred electrophoretically onto 0.45 mm Optitran membranes (Schleicher & Schuell) . LMP1 was identified with CS1-4 (Dako) or a pool of rat monoclonal antibodies specific for LMP1 (clones 7E10, 8G3, 1G6, 7G8) (Ascenion). Mouse monoclonal antibodies anti-TRAFs 1, 2, and 3 (Santa Cruz Biotechnology) were used for TRAFs 1, 2, and 3. Antiphospho serine 473 Akt, a-total Akt, a-phospho JNK, a-total JNK, aphospho p38, and a-total p38 antibodies were used for phospho-specific blots as directed by the manufacturer (Cell Signaling). Anti-b-actin was obtained from Santa Cruz Biotechnology.
Electromobility shift assay EMSAs were performed as described previously (Cogswell et al., 2000) . Briefly, an oligonucleotide (UV21) of the NF-kB site from the H-2K b gene (CAGGGCTGGGGATTCCCCA TCTCCCACAGTTTCACTTC) was labeled with [a-32 P]dCTP using the Klenow fragment from DNA polymerase I. Nuclear extract (2 mg) was incubated with radiolabeled probe. For supershift assays, 0.5-5 mg antibody was incubated with extracts prior to the addition of radiolabeled probe. Antibodies used were a-p105/p50, a-Rel-B, a-c-Rel, (Santa Cruz), a-p65 (Rockland), and a-p100/p52 (Upstate).
DNA purification and PCR Mouse spleen tissue was digested overnight at 551C with proteinase K (1 mg/ml) in 50 mM Tris, pH 8, 100 mM EDTA, 100 mM NaCl, 1% SDS, and 1 mM CaCl 2 . RNase was added to 250 mg/ml and the samples were incubated for 2 h at 371C. The DNA was phenol/chloroform extracted and ethanol precipitated. p53 exons 5-8 were amplified from 300 ng DNA by PCR using Taq polymerase (Promega) using primers 5 0 ACACCT GATCGTTACTCGGCTTGTC and 3 0 AAGAGGTGACTTT GGGGTGAAGCTC (Effert et al., 1992 ). Nested PCR reactions were then performed from 3 ml of the initial reaction for exon 5, 5 0 primer above and 3 0 primer AGGCTGCCAGT CCTA; exon 6, 5 0 primer CGGCTTCTGACTTAT and 3 0 primer CTGGAGTCAACTGTC; exon 7, 5 0 primer AGCGA CTTCACCTGG and 3 0 primer GGAAGAAACAGGCTA AC; and exon 8, 5
0 primer ACTGCCTTGTGCTGG and 3 0 primer GGAAGAAACAGGCTAAC. The respective 5 0 primers were used for sequencing the individual exons. The samples were sequenced at the University of North CarolinaChapel Hill Automated DNA Sequencing Facility on a model 3100 genetic analyzer (Applied Biosystems Division, PerkinElmer Cetus) by using the ABI Prism dye terminator cycle sequencing ready reaction kit with AmpliTaq DNA polymerase FS (Applied Biosystems Division, Perkin-Elmer Cetus). Differential PCR for allelic loss was performed with the b-globin reference gene as described previously (Effert et al., 1992) . Amplification of sequences in exons 5 and 8 of p53 in conjunction with the amplification of a 167-bp sequence within the b-globin gene was performed using primers: b-globin, 5 0 -AT TCCGTAGAGCCACACCAT and 3 0 -CCATGATGTCTGTT TCTGGGG; exon 5, 5 0 -ACACCTGATCGTTACTCGGC and 3 0 -CTAACCCCACAGGCGGTGTT (270-bp sequence), and exon 8, 5 0 -TCAGGATGGGGCCCAGCTTT and 3 0 -CCGCC TGCGTACCTCTCTTT (208-bp sequence).
